MRAs and SGLT2 Inhibitors: The Best of Both Worlds in HFrEF MRAs and SGLT2 Inhibitors: The Best of Both Worlds in HFrEF

What benefits might the use of these treatments together offer in the management of heart failure with reduced ejection fraction?JACC: Heart Failure

Source: Medscape Today Headlines - June 22, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news